Results of a clinical study evaluating the potential role of a Perfluorodecalin (PFD)-infused gel patch in laser-assisted tattoo removal were presented at the American Society for Dermatologic Surgery (ASDS) Annual Meeting.

“It is estimated that close to 25% of the US population has some sort of tattoo and eventually 50% will want to have those tattoos removed.  However, laser-assisted tattoo removal has its limitations,” said Dr. Brian S. Biesman, Clinical Assistant Professor of Dermatology at Vanderbilt University Medical Center and principal investigator for the pivotal clinical trial.  “The goal of this study was to see if using the DeScribe Transparent PFD Patch, as an accessory to laser tattoo removal procedures, can increase patient satisfaction by cutting down on the number of treatments needed to fully remove an unwanted tattoo.”

Dr. Biesman presented his formal clinical experience at the American Society for Dermatologic Surgery meeting, along with the results of a 17 patient pilot study using the DeScribe Transparent PFD Patch.  Use of the patch conclusively demonstrated faster clearance with higher subject satisfaction than conventional single pass treatment. Study participants presented with blue or black tattoos and were treated with a standard Q-switched Alexandrite laser at maximum tolerable fluence.  A single laser pass was delivered on the control side without the DeScribe patch, yet 4 passes were routinely achievable if the PFD Patch was used. The study found that the majority of subjects showed accelerated clearing on the patch side of the tattoo, and preferred the patch-treated side versus the control. Additionally, no adverse events were observed.